Stifel lowered the firm’s price target on Argenx (ARGX) to $1,222 from $1,227 and keeps a Buy rating on the shares following an in-line Q1 report. Despite seasonality headwinds, management commentary emphasized consistent underlying growth which sets up the stock well after some worry of a weak quarter. The firm believes consensus of $5.9B seems beatable, especially with potential tailwinds from the seronegative launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Posts 63% Q1 Sales Surge as New CEO Steers Expansion of Autoimmune Portfolio
- Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline
- Argenx Installs New CEO Karen Massey as Van Hauwermeiren Becomes Chair After AGM Approvals
- Argenx Completes First Safety Study for New Antibody ARGX-213
- Argenx Showcases Broad VYVGART and Pipeline Gains at AAN 2026 to Bolster Neuromuscular Leadership